HLA-C and respiratory tract infectious disorder: For 228 and 23 episodes of respiratory infection with ESBL-E(-)/HLAC-E(−) and ESBL-E(−)/HLAC-E(+) intestinal carriage, respectively, 28/228 (12.3%) and 10/23 (43.5%) were treated with carbapenems.